TY - JOUR
T1 - Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer
AU - Flavia Di Renzo, M.
AU - Olivero, M.
AU - Giacomini, A.
AU - Porte, H.
AU - Chastre, E.
AU - Mirossay, L.
AU - Nordlinger, B.
AU - Bretti, S.
AU - Bottardi, S.
AU - Giordano, S.
AU - Plebani, M.
AU - Gespach, C.
AU - Comoglio, P. M.
PY - 1995
Y1 - 1995
N2 - The c-met oncogene encodes the receptor for hepatocyte growth factor/scatter factor, a potent mitogen for epithelial cells that also promotes cell motility and invasiveness. We have studied the changes of c-met gene expression that occur during the progression of colorectal tumors. Sixteen adenomas, 123 primitive carcinomas, and 25 liver metastases were examined. In several instances it was possible to compare same-patient samples of normal colon mucosa against primary tumor and primary carcinoma against synchronous metastasis. The expression of the c-met gene was increased from 5- to 50-fold in about 50% of tumors, at any stage of progression, and in 70% of clver metastases. Overexpression was associated with amplification of the c-met gene in only 10% of carcinomas, but in 8 of 9 metastases examined. These data suggest that overexpression of the c-met oncogene contributes a selective growth advantage to neoplastic colorectal cells at any stage of tumor progression. Moreover, amplification appears to give a further selective advantage for the acquisition of metastatic potential.
AB - The c-met oncogene encodes the receptor for hepatocyte growth factor/scatter factor, a potent mitogen for epithelial cells that also promotes cell motility and invasiveness. We have studied the changes of c-met gene expression that occur during the progression of colorectal tumors. Sixteen adenomas, 123 primitive carcinomas, and 25 liver metastases were examined. In several instances it was possible to compare same-patient samples of normal colon mucosa against primary tumor and primary carcinoma against synchronous metastasis. The expression of the c-met gene was increased from 5- to 50-fold in about 50% of tumors, at any stage of progression, and in 70% of clver metastases. Overexpression was associated with amplification of the c-met gene in only 10% of carcinomas, but in 8 of 9 metastases examined. These data suggest that overexpression of the c-met oncogene contributes a selective growth advantage to neoplastic colorectal cells at any stage of tumor progression. Moreover, amplification appears to give a further selective advantage for the acquisition of metastatic potential.
UR - http://www.scopus.com/inward/record.url?scp=0028946604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028946604&partnerID=8YFLogxK
M3 - Article
C2 - 9815967
AN - SCOPUS:0028946604
VL - 1
SP - 147
EP - 154
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 2
ER -